Reducing cardiometabolic risk with semaglutide in type 1 diabetes (RESET1): Study protocol of a phase 2 double-blinded randomised placebo-controlled trial.
Ruth FramptonJennifer R SnaithSamantha L HockingDeborah Jane Holmes-WalkerNicholas OlsenJerry R GreenfieldPublished in: Diabetic medicine : a journal of the British Diabetic Association (2024)
The REducing cardiometabolic risk with SEmaglutide in Type 1 diabetes study will investigate whether semaglutide, a long acting glucagon-like peptide receptor agonist, can improve markers of cardiometabolic health in T1D. Underlying mechanisms predicting response, including insulin resistance and incretin hormone status, will also be explored.
Keyphrases
- type diabetes
- study protocol
- insulin resistance
- clinical trial
- double blind
- glycemic control
- randomized controlled trial
- healthcare
- open label
- public health
- cardiovascular disease
- mental health
- adipose tissue
- high fat diet
- metabolic syndrome
- skeletal muscle
- placebo controlled
- polycystic ovary syndrome
- risk assessment
- health information